Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Multiple Myeloma 181Recurrence 32Neoplasms, Plasma Cell 16Lymphoma 11Waldenstrom Macroglobulinemia 6Neoplasms 6Lymphoma, Mantle-Cell 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Smoldering Multiple Myeloma 4Leukemia 4Small Cell Lung Carcinoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Plasma Cell 3Hodgkin Disease 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Disease 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Salivary Gland Adenoma, Pleomorphic 1

Interventions

Everolimus 10Octreotide 7pasireotide 5lanreotide 5gallium Ga 68 dotatate 5lutetium Lu 177 dotatate 3cabozantinib 3Sunitinib 3Nivolumab 3ganitumab 2fluorodopa F 18 2Temozolomide 2Ga(III)-DOTATOC 2Erlotinib Hydrochloride 2Capecitabine 2Bevacizumab 2zimberelimab 1veliparib 1telotristat ethyl 1surufatinib 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1olaparib 1nintedanib 1ibrutinib 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × carfilzomib × Clear all
NCT02318784 2023-12-05

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

SCRI Development Innovations, LLC

Phase 2 Completed
62 enrolled 10 charts
Endocrine

Carcinoid Tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡